Endocyte, Inc.

$ECYT - Nasdaq - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 1
WATCHLISTS

COMMUNIQUÉ DETAILS

posts/post

Press Release $ECYT Endocyte, Inc.

0 COMMENTs 27 Aug
Up 0 0 Down
Endocyte to Present at Upcoming Conferences in September

WEST LAFAYETTE, Ind., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming conferences in September:

Morgan Stanley Global Healthcare Conference – Tuesday, Sept. 10, at 10 a.m. EDT. The conference will be held at the Grand Hyatt New York.

Baird 2013 Health Care Conference – Wednesday, Sept. 11, at 10:15 a.m. EDT. The conference will be held at The New York Palace in New York.

Stifel Healthcare Conference 2013 – Thursday, Sept. 12, at 4:25 p.m. EDT. The conference will be held at The Four Seasons Hotel in Boston.

Webcast information can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com.  All webcasts will be archived shortly after each live event and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,
         (212) 362-1200, stephanie@sternir.com
         Martina Schwarzkopf, Ph.D., Russo Partners,
         (212) 845-4292, martina.schwarzkopf@russopartnersllc.com
         Tony Russo, Ph.D., Russo Partners,
         (212) 845-4251, tony.russo@russopartnersllc.com
Source: Endocyte, Inc.
SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/bJsD

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?